Paris La Défense, July 19, 2026

DISCLOSURE OF A RELATED PARTY AGREEMENT PURSUANT TO ARTICLES L. 22-10-13 AND R. 22-10-17 OF THE FRENCH COMMERCIAL CODE

Pursuant to Articles L. 22-10-13 and R. 22-10-17 of the French Commercial Code, the following information is provided on a related party agreement recently entered into by Icade (the "**Company**"):

Nature and purpose of the agreement

On July 18, 2026, Praemia Healthcare and OPPCI IHE Healthcare Europe ("**IHE**"), vehicles managed by Praemia REIM and owned respectively at 21.61% and 59.39% by Icade, have entered into a promise of sale concerning all of the shares of *Fundo de Investimento Imobiliario Fechado Saudeinveste*, a Portuguese real estate investment fund holding a portfolio of four healthcare assets (the "**Portfolio**") located in Lisbon, Porto, Albufeira, and Lagos in Portugal (the "**Sale**").

Since the Sale deviates from the terms of the binding sale and purchase agreement entered into on June 13, 2023 by Icade with Praemia REIM and the minority shareholders of Praemia Healthcare and IHE, Icade entered into with the latter, on July 17, 2026, a protocol agreement (the "**Protocol**"), which authorizes the Sale under these derogatory conditions and provides that the proceeds from the transfer received by Praemia Healthcare will be mainly distributed to Icade as part of an unequal capital reduction. In return, Icade has committed to paying indemnities to minority shareholders of IHE and Praemia Healthcare, including Predica Prévoyance Dialogue du Crédit Agricole ("**Predica**"), a life insurance subsidiary of Crédit Agricole Assurances, a shareholder holding 18.85%[1] of the Company's capital.

The payment by Icade of the compensation owed to the minority shareholders of IHE and Praemia Healthcare would only occur subject to Icade receiving a share of the sale proceeds to be paid to it by IHE and Praemia Healthcare respectively under the terms of the Protocol.

Prior approval by the Board of Directors of Icade

The Board of Directors of the Company, as part of a written consultation dated July 1, 2026, authorized, after review, the signing of the Protocol, in accordance with the provisions of Article L. 225-38 of the French Commercial Code. Mr. Raphaël Appert and Mrs. Florence Habib-Deloncle, as a result of their responsibilities within the Crédit Agricole group, did not participate in this written consultation.

[1] As of June 30,2026

Financial conditions

As part of the Sale, the Portfolio is valued at €186 million, in line with the value recorded in Icade's NAV as of December 31, 2025. The share attributable to Icade in the context of the completion of the Portfolio Sale amounts to approximately €75 million.

The maximum amount of compensation that could be paid by Icade to Predica under the Protocol is estimated at €2.3 million.

Reasons justifying the interest of this agreement for the Company

The Board of Directors noted the interest that there is for the Company in entering into the Protocol considering the conditions of the Sale and the share of the sale proceeds to be allocated to Icade. This Sale is in line with the objectives of the ReShapE strategic plan and allows the Company to continue its withdrawal from its international healthcare division.

This agreement will be submitted to the Company's shareholders' general meeting called to approve the accounts of the financial year ending December 31, 2026.

It is recalled that the Company's annual financial statements as of December 31, 2025, show a loss of €(20,959,219.97) and that the consolidated financial statements as of December 31, 2025, show a loss (group share) of €(123,031,840.29).